IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventor: Adeela Kamal et al.) Group Art Unit: Not Yet Assigned
Serial Number: 10/538,687	Examiner: Not Yet Assigned
Filing Date: June 10, 2005	CONFIRMATION NO: 3645
Title: Cytotoxins and Diagnostic Imaging Ag Comprising HSP90 Ligands	ents)

Electronically Fled on March 222006 b

Mail Stop IDS Commissioner of Patents P.O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. \$1.97

Sir

Applicants hereby submit an Information Disclosure Statement along with attached forms PTO/SB/08A and B. A copy of each listed publication is being submitted, if required, pursuant to 37 C.F.R. §§197-1.98, as indicated below.

Applicants respectfully request that the listed information be considered by the Examiner and be made of record in the above-identified application. Applicants further request that the Examiner initial and return the attached forms PTO/SB08A and B in accordance with MFEP 8609.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement is not intended to represent that a search has been made or that the information cited in the statement is, or is considered to be, prior art or material to patentability as defined in §1.56.

⊠ because		$\S1.97(b)$. This Information Disclosure Statement should be considered by the Office
		 It is being filed within 3 months of the application filing date of a national application and is other than a continued prosecution application under §1.53(d); —OR.—
		(2) It is being filed within 3 months of entry of a national stage as set forth in §1.491 in an international application; —OR—
	\boxtimes	 It is being filed before the mailing date of the first Office Action on the merits; OR
		(4) It is being filed before the mailing of a first Office Action after the filing of a request for continued examination under §1.114.
	specific office a closes	$\S_1 S \gamma (s)$. Although this Information Disclosure Statement is being filed after the period in 37 CFR $\S_1 \gamma (s)$, above, it is filed before the maining date of the earlier of (1) a final tion under $\S_1 .113$, (2) a notice of allowance under $\S_1 .311$, or (3) an action that otherwise in the statement should be considered it is accompanied by one of:
		a certification as specified in §1.97(e) provided concurrently herewith;
		a fee of \$180.00 as set forth in $\S1.17(p)$ authorized below, enclosed, or included with the payment of other papers filed together with this statement.
	date of §1.311,	$\S1.97(d)$. Although this Information Disclosure Statement is being filed after the mailing the earlier of (1) a final office action under $\S1.113$ or (2) a notice of allowance under it is being filed before payment of the issue fee and should be considered because it is unied by:
	A.	a certification as specified in §1.97(e); and
	В.	a fee of \$180.00 as set forth in $\S1.17(p)$ is authorized below, enclosed, or included with the payment of other papers filed together with this Statement.
		$\S1.97(e).$ A certification signed by an Attorney of Record is provided herewith as under 37 CFR $\S1.97(b)$ and (c).
\boxtimes	37 CFF	§1.98(a)(2). The content of the Information Disclosure Statement is as follows:
		Copies of each of the references listed on the attached Form PTO/SB/08A are enclosed herewith. - OR -
		Copies of U.S. Patent Documents (issued patents and patent publications) listed on the attached Form PTO/SB/08A are NOT enclosed. — AND/OR —
	⊠	Copies of Foreign Patent Documents and/or Non Patent Literature Documents listed on the attached Form PTO/SB/08A are enclosed in accordance with 37 CFR §1.98(a)(2). — AND/OR —
		Copies of pending unpublished U.S. patent applications are enclosed in accordance with 37 CFR §1.98(a)(2)(iii).

		Pursuant to 37 CFR §1.98(a)(3)(i), a concise explanation of the relevance of each patent, publication or other information provided that is not in English is provided herewith.
		Pursuant to 37 CFR §1.98(a)(3)(ii), a copy of a translation of the non-English language reference(s) is provided herewith
		ed are copies of search report(s) from corresponding patent application(s), submitted in ance with MPEP 609 D in support of the attached certification under 37 CFR §1.97(c)(1).
⊠	of \$0.	thorization. The Commissioner is hereby authorized to charge the above-referenced fees 00 and charge any additional fees or credit any overpayment associated with this mication to Deposit Account No. 23-2415 (Docket No. 23983-716.832).
		Respectfully submitted,
		WILSON SONSINI GOODRICH & ROSATI

37 CFR \$1.98(a)(3). The Information Disclosure Statement includes non-English patents and/or

Dated: March 21,2006

Samir Elamrani, Ph.D.
Reg. No. 43,601

650 Page Mill Road Palo Alto, CA 94304-1050 (650) 493-9300 Customer No. 021971

references.

PTO/SB/08A (07-05)

Approved for use through 07/31/2006 OMR 0611-0011 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

				Con	nplete if Known
Substitute fi	or form 144	PTO		Application Number	10/538,687
INFORM	IATION	DISC	LOSURE	Filing Date	June 10, 2005
STATEM	STATEMENT BY APPLICANT (Use as many sheets as necessary)		First Named Inventor	Adcela Kamal et al.	
(Use as			cessary)	Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned
Sheet	1	of	7	Attorney Docket Number	23983-716.831

U.S. PATENT DOCUMENTS

Examiner Cite Initials* No.1	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where	
initials*	140.	Number-Kind Code ² (if Instant)	MM-DD-YYYY	Applicant of Cited Document	Relevant Passages or Relevant Figures Appear
	\rightarrow		-		

FOREIGN PATENT DOCUMENTS

Initials*	No.1	Foreign Pittent Document	MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Where Relevant Passages or	100
	144	Country Code" - Number" - Kind Code" (f frame)			Relevant Figures Appear	١.
	1	WO-03-072794 A1	09-04-2003	Upjohn Co.		П
	2	WO-03-066005 A2	08-14-2003	Conforma Therapeutics		т
	3	WO-03-050295 A2	06-19-2003	Conforma Therapeutics		Т
	4	WO-03-041643 A2	05-22-2003	Conforma Therapeutics		╴
	5	WO-03-037860 A2	05-08-2003	Conforma Therapeutics		т
	6	WO-03-026571 A2	04-03-2003	Conforma Therapeutics		т
	7	WO-02-094196 A2	11-28-2002	Sloan Kettering		Т
	8	WO-02-069900 A2	09-12-2002	Conforma Therapeuties		Т
	9	WO-02-09696 A1	02-07-2002	Sloan Kettering		т
	10	WO-02-036171 A1	05-10-2002	Sloan Kettering		т
	11	WO-02-036075 A2	05-10-2002	Sloan Kettering		т
	12	WO-02-02123 A1	01-10-2002	Trustees of Boston U.		т
	13	WO-01-72779 A1	10-01-2001	Duke U.		т
	14	WO-99-51223 A1	10-14-1999	U. of Pittsburgh		т
	15	WO-98-051702 A1	11-19-1998	Sloan Kettering		Т
	16	WO-93-14215 A1	07-22-1993	Pfizer Inc.		т

Signature Contidered Signiture

| Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signiture | Signi exceedings. Indicate in metrical consistency, session in our contains in metrical consistency of a few in the control of the c

Date

Translation is attached.

transacron is attactors.
This collection of information is required by 37 CPR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, control of proteins in approximate the completed application form in the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this busines, should be sent to the Chief Information Officer, U.S. Paget and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Version Ch. | Francis Scientific

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information utiles: it contains a valid OMB control number. Complete if Known Substitute for form 1449/PTO Application Number 10/538.687 INFORMATION DISCLOSURE Filing Date June 10, 2005 STATEMENT BY APPLICANT First Named Inventor Adecla Kamal et al. (Use as many sheets as necessary) Art Unit Not Yet Assigned Examiner Name Not Yet Assigned Attorney Docket Number 23983-716 832 Sheet of

> NON PATENT LITERATURE DOCUMENTS Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the

Examiner Initials*	Cite No.1	item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	Ta
	17	AUSUBEL et al., Current Protocols in Molecular Biology, John Wiley & Sons, NY 1994	-
	18	BAGATELL, R. et al., "Induction of a Heat Shock Factor I-dependent Stress Response Alters the Cytotoxic Activity of Hsp-90-binding Agents," Clinical Cancer Res., Aug. 2000, Vol. 6, pp.3312- 3318	
	19	BERGE et al., "Pharmaceutical Salts," J. Pharm. Sci. 66:1-19 (1977)	
	20	BOEHM et al., J. Org. Chem. 51:5447-5450 (1986)	
	21	BUCHNER, Trends Biochem. Sci. 24:136-141 (1999)	
	22	BUCHWALD et al., Surgery 88:507 (1980)	-
	23	CAILLEAU, R. et al., "Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization," In Vitro 14:911-915, 1978, PubMed 730202	
	24	CAPLAN, Trends Cell. Biol. 9:262-258 (1999)	
	25	CHIOSIS, G. et al., "A small molecule designed to bind to the adenine nucleotide pocket of Happ0 causes Her2 degradation and the growth arrest and differentiation of breast cancer cells," Chem. & Biol. 8 (2001) 289-28	
	26	COREY et al., J. Am Chem. Soc., 96: 5581-5583 (1974)	

Examiner	Date	
signature	Considered	

*EXAMINER: Initial if reference considered, whether or not citation is an conformance with MPEP 609. Draw line through citation if not in conformance and not

considered. Include cupy of this form with next communication to applicate a content made to the content of the gathering, preparing, and submitting the completed population form to the USFIO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or negations for reducing this burden, should be not to the Chief Individual Conf. Trailments Office, P.O. Box 14(3), Alexandric, W. 22213-14(8). Do NOT SEND PROSS OR COMPLETED FORMS TO THE ADDRESS. SENDE TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

PTO/SB/06B (07-05) Approved for use through 07/31/2006. OMB 0651-0031

Approved for use though 970/1/2006. OMB 0051-0051

U.S. Paines and Tradermark Office, U.S. DEPARTMENT OF COMMERCE

Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information unless it contains a valid OMB control number.

				Complete if Known		
Substitute for form 1449/PTO		Application Number	10/538,687			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Filing Date	June 10, 2005			
		First Named Inventor	Adcela Kamal et al.			
(Use a	(Use as many sheets as necessary)		Art Unit	Not Yet Assigned		
				Examiner Name	Not Yet Assigned	
Sheet	3	of	7	Attorney Docket Number	23983-716.832	

		NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, cic.), date, page(s), volume-issue number(s), publisher, city and/or country where publisher.	T ²	
	27	CHUMPRADIT, S. et al., "Fluorinated and iodinated dopamine agents: D2 imaging agents for PET and SPECT," J. of Med. Chem. 36 (2):221-8 (1993)		
	28	DAI, K. et al., J. Biol. Chem. 271:22030-4 (1996)		
	29	DE LA TORRE-BUENO, J. et al., Modern Pathology 13:221 A (2000)		
	30	ERLICHMAN et al., Proc. AACR (2001) 42, Abstract 4474		
	31	ENG et al., Bull. Chim. Soc. Belges 95:895-914 (1986)		
	32	FEDERAL REGISTER 66 (129): 35443-35444		
	33	GOODMAN and GILMAN, The Pharmacological Basis of Therapeutics, current ed., Pergamon Press	_	
	34	GOODSON, Medical Applications of Controlled Release, Vol. 2, pp. 115-138 (1984)		
	35	GRENERT, J.P. et al., J. Biol. Chem. 272:23843-50 (1997)		
	36	HANSON et al., Int. J. Appli. Radiat. Isot. 35:810-812 (1984)	-	
	37	HARLOW et al., Antibodies: A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1988		
	38	HARTMANN, F. et al., Int. J. Cancer 70:221-9 (1997)		

*EXAMINER: Initial if reference considered, whether or not clinifon is in conformance with MFFF 669. Draw line through clinifon if not in conformance and not

"SAAALINE" Initial of reference commons, wenter or on cases an a commonster wat TVP ON. Name or extend you causes a non-monomers are not "Applicant" in wage of companies to a companies or more proposed by the pass a clock work how IT Digitals happage Tractation to a tacked by TVP ON TVP O

PTO/SB/08B (07-05)

Approved for use through 07/31/2006 OMB 0651-0031
U.S. Pakou and Trademark Office; U.S. DEPARTMENT OF COMMERCE

	1.00.000			Com	plete if Known
Substitute for form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use at many sheets at necessary)		Application Number	10/538,687		
		Filing Date	June 10, 2005		
		First Named Inventor	Adecla Kamal et al.		
(Use a	s many sho	ets as neo	essary)	Art Unit	Not Yet Assigned
				Examiner Name	Not Yet Assigned

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, scales, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	39	HOWARD, G., "Labeling Proteins with Fluorochromes," Methods in Nonradioactive Detection, T. Hward, Ed. Appleton and Lange, Norwalk Conn USA 1993, pp. 39-68	
-	40	JALILIAN et al., J. Pharm. Pharmaceut. Sci. 3:114-124 (2000)	
	41	KELLAND, L.R. et al., "DT-Displorase Expression and Tumor Cell Sensitivity to 17- Allylarnino, 17-Demethoxygeldanamycia, An Inhibitor of Heat Shock Protein," J. Nad. Cancer Inst., 17 Nov. 1999, Vol. 91, No. 22, pp.1940-1949	
	42	KUROKAWA, H. et al., Cancer Res. 60:5887-5894 (2000)	
	43	LANGER, Science 249:1527-1533 (1990)	
	44	MANDELKERN et al., "Positron emission tomography in cancer research and treatment," Technologies in Cancer Research and Treatment 1(6):423-39 (2002)	
	45	MARCU, M.G. et al., "The Heat Shock Protein 90 Antagonist Novobiocin Interacts with a Previously Unrecognized ATP-Binding Domain in the Carboxyl Terminus of the Chaperone," J. Biol. Chem, 24 Nov. 2000, Vol. 274, No. 47, pp.37181-37186	
	46	MILLER, P. et al., Cancer Research 54:2724-2730 (1994)	
	47	MIMNAUGH, E.G. et al., J. Biol. Chem. 271:22796-801 (1996)	
	48	MITCHELL, M.S. and PRESS, M.F., Semin. Oncol. Suppl.12:108-116 (1999)	

Examiner Date signature *EXAMINER. Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not

"TAXAMENIA". Intil of reference consistent, where or not achieve his incomformers with MPP 60. Date for through cactions of not it restlymates and not "Applicated values in charged his pages for all to page of the comportance and not "Applicated values in charged and his pages for making in the page of the comportance of the comportan

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE Under the paperwork Reduction Act of 1995, an occusion required to reasonal to a collection of information unless it contains a valid OMR control number.

					The state of the s		e if Known	Tanana Ca
Substitute for form 1449/PTO INFORMATION DISCLOSURE					Application Number 10/538,687			
					Filing Date		June 10, 2005	
STATEMENT BY APPLICANT					First Named Invent	or	Adocla Kamal et al.	
(Use as many sheets as necessary)					Art Unit		Not Yet Assigned	
Sheet 5 of 7					Examiner Name		Not Yet Assigned	
				7	Attorney Docket No	ımber	23983-716.832	
				NON PATE	NT LITERATURE	DOCUMENT	rs	
Examiner Cite		Includ item (le nan book,	magazine, journal,	CAPITAL LETTERS), t , serial, symposium, catale shlisher, city and/or count	og. etc.), date, pa	(when appropriate), title of the ige(s), volume-issue number(s),	T ²
	49	MUIS	MUISE-HEIMERICKS et al., J. Biol. Chem. 273:29864-72 (1998)					
	50	NUCI	EAR	MEDICINE AN	ID BIOLOGY, 20(1), pp	.75-77 (1993)	-	
	51	PANA	RET	OU et al., EMBO	J. 17:4829-4836 (1998))		
	52 PRESS, M. et al., Modern Pathology 13:225A (2000))		
	53	PRES	TWI	CH et al., Tetrahe	dron 40:529-537 (1984)			
	54	PROD	RON	fOU, C. et al., Ce	ell 90:65-75 (1997)			
	55	QUAI Delive	ered v	et al., "Synergistic ria Acid-Labile D	c Photoxicity of Chloros iplanmenylcholine-Folar	luminum Phtha e Lipsomes," Ir	locyanine Tetrasulfonate nt. J. of Cancer 93:384-392	
	56			ON PHARMACE	EUTICAL SCIENCES, o	current ed., Mac	k Publishing Co., Easton PA	
	57	SAMBROOK et al., Molecular Cloning: A Laboratory Manual, 2 nd ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY 1989						
58 SAUDEK et al., N. Eng. J. Med. 321:574 (19)					fed. 321:574 (1989)			
	59	SCHEIBEL et al., PNAS USA 96A:1297-1302 (1999)						
	60	SCHN	EID	ER et al.,, PNAS	USA 93:14536-41 (1996)		
	-					Date		_
Examiner signature						Date Considered		

TEXAMONE: Intell Cordence considered, Austre or so clotics in conformance with METF 60: Date for through Citation if not in conformance and not continued. Including copy of this force with societies. Including copy of this force with societies. Including copy of this force with societies. Including copy of the force with societies. Applicate is upon continued to prepare the copy of the INFO of the I

Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

PTO/SB/08B (07-05)

Appeaved for use through 07/31/2006. OMB 0651-0051 U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

				Com	Complete if Known		
Substitute f	or form 14	49/PTO		Application Number	10/538,687		
			OSURE	Filing Date	June 10, 2005		
STATEM				First Named Inventor	Adeela Kamal et al.		
(Use	is many sho	ets as necess	iary)	Art Unit	Not Yet Assigned		
				Examiner Name	Not Yet Assigned		

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	т,
	61	SCHULTE et al., Biochem. Biophys. Res. Commun. 239:655-9 (1997)	
_	62	SCHULTE et al., J. Biol. Chem. 270:24585-8 (1995)	
	63	SEFTON, CRC Grit. Ref. Biomed. Eng. 14:201 (1987)	
	64	SEGNITZ, B. and GEHRING, U., J. Biol. Chem. 272:18694-18701 (1997)	
	65	SEPP-LORENZINO et al., J. Biol. Chem. 270:16580-16587 (1995)	
	66	SMITH, D.F. et al., Mol. Cell. Biol. 15:6804-12 (1995)	
	67	STEBBINS et al., Cell 89:239-250 (1997)	
	68	STEPANOVA et al., Genes Dev. 10:1491-1502 (1997)	
	69	TREAT et al., <u>Liposomes in the Therapy of Infectious Disease and Cancer</u> , Lopez-Bernstein and Fidler (eds.), Liss, NY USA pp.353-365	
	70	VASILEVSKAYA et al., Cancer Res. 59:3935-40 (1999)	-
	71	VOGES, ROLF and PLEISS, ULRICH, eds., <u>Synthesis and Applications of Isotopically Labelled</u> <u>Compounds</u> , Vol. 7. Ulrich Pleiss, John Wiley & Sons Ltd. (2001)	

signature			Considered	
*EXAMINER: Instial if	reference considered, w	dether or not estation is in conformance	eith MPSP 609. Draw line the	ough citation if not in conformance and not

TOUGHER, intell of reference consistent, whether or an extension is non-formance with MFF 60. Date the through chicked for at a conformance and not applicated variety critical confusions and an experimental confusions. A proper contribution of the proper confusion is confusionally applicated values (critical designation may include by 17 CFR 18. The information is expensed to define or written is benefit by the public which in the life (and by the INSTO publication is required by the INSTO publication of the INSTO publication is the life of the INSTO publication is the life of the INSTO publication is the INSTO publication in the INSTO publication is the INSTO publication in the INSTO Time will not operating upon the judgical card any comment on the compared that the INSTO publication is not not located to the INSTO publication in the INSTO Time will not operating upon the judgicate card any comment on the compared to the INSTO publication in the INSTO Time will not operating upon the judgicate card any comment on the INSTO publication in the INSTO Time will not operating upon the judgicate card any comment on the INSTO publication in the INSTON publi

If you need assistance in completing the form, call 1-800-PTO 9199 and select option 2.

Examiner

PTG/SB/08B (07-05) Approved for use through 07/31/2006. OMB 0651-003

Approved for use immugh 07/31/2006. OMB 0651-0633
U.S. Painest and Taschwark Office, U.S. DePARTMENT OF COMMERCE
Under the paperwork Reduction Act of 1995, no persons required to respond to a collection of information universit constants a Valid OMB control number.

				Complete if Known		
Substitute i	or form 14	49/PTO		Application Number	10/538,687	
			LOSURE	Filing Date	June 10, 2005	
			PLICANT	First Named Inventor	Adeela Kamal et al.	
(Use	as many she	els as ne	ressory)	Art Unit	Not Yet Assigned	
				Examiner Name	Not Yet Assigned	
Sheet	7	of	7	Attorney Docket Number	23983-716.832	

		NON PATENT LITERATURE DOCUMENTS						
Examiner Initials*	Cite No.1	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, estalog, etc.), date, page(8), volume-issue number(s), publisher, city and/or country where published.						
	72	WHITESELL et al., PNAS USA 91:8324-8328 (1994)						
	73	ZIMNY et al., "Positron emission tomography scanning in gynecologic and breast cancer," Curr. Op. in Obstetrics and Gynecology 15(1):69-75 (2003)						
	74	RINEHART, JR., K.L. and SHIELD, L.S., "Chemistry of the Ansamycin Antibiotics," <u>Progress</u> in the Chemistry of Organic Natural <u>Products</u> , pp.231-307, 1975						
		*						

*EXAMINER: Initial if reference considered, v	electher or not citation is in conformance with MPEP 609. Draw line through citation	on if not in confirmence and not

Commission. Since you did not never him not make a manuscription and prices.

"Opportunity stages of the prices of

If you need assistance in completing the form, cell 1-800-PTO-9199 and select aution 2.

Examiner